SIPONIMOD FUMARIC ACID (Mayzent®)

Clinical Indication

Secondary progressive multiple sclerosis in adults

Comments

In line with NICE TA656

Date of classification

February 2020

Review date

February 2020

Red

Drugs which should be prescribed only by hospital specialists (clinical review by specialist as appropriate and annually as a minimum).